-
All NSAIDs May Be Linked to Increased Risk of Heart Attack (or Not)
June 2005 BMJ Article Calls Into Doubt Cardiovascular Safety of All NSAIDs There is new evidence that all selective and nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with an increased risk of having a…
-
Case Report: Adderall-induced Heart Attack in Young Boy
Reports of Sudden Unexplained Death (SUD) Involving Children Being Studied by FDA After Adderall Withdrawn in Canada An article entitled "Myocardial infarction in an adolescent taking Adderall", by Pritesh J. Gandhi, et.al., was published…
-
Merck Did Not Test Safety of Vioxx on Heart Before it Was Brought to Market in 1999
Merck Epidemiologist Santanello: “At that time we didn’t think there was any risk.” According to The Associated Press (AP), Merck & Co.’s top epidemiologist, Nancy Santanello, gave testimony at the Ernst trial in Texas…
-
First Federal Court Vioxx Trial Set for November 2005 in New Orleans
Merck Maintains No "Global Settlement" Stance Despite Thousands of Vioxx Cases Filed to Date U.S. District Judge Eldon Fallon, the federal court judge overseeing the Vioxx MDL (Multi-district Litigation), announced on July 19, 2005…
-
First Vioxx Lawsuit Trial Starts in Brazoria County, Texas: Ernst vs. Merck
Vioxx Trial in Texas Expected to Be at Least Five Weeks Before Jury Verdict Merck & Co. is currently engaged in the first trial of a lawsuit involving Vioxx, and there are thousands of…
-
Duragesic Pain Patch: Johnson & Johnson Adds Warning to Label and Sends “Dear Doctor” Letter
FDA Follows With Public Health Advisory on Duragesic and Other Fentanyl Patches On July 8, 2005 Johnson & Johnson Inc. added warnings about possible misuse and abuse to its Duragesic pain patch package insert…
